Modality
Cell Therapy
MOA
ALKi
Target
FcRn
Pathway
RAS/MAPK
Ovarian Ca
Development Pipeline
Preclinical
~Dec 2021
→ ~Mar 2023
Phase 1
Jun 2023
→ Nov 2027
Phase 1Current
NCT07254783
2,270 pts·Ovarian Ca
2023-06→2025-06·Active
NCT03317682
1,090 pts·Ovarian Ca
2024-09→2027-11·Not yet recruiting
3,360 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-06-279mo agoInterim· Ovarian Ca
2027-11-131.6y awayInterim· Ovarian Ca
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1
Active
P1
Not yet…
Catalysts
Interim
2025-06-27 · 9mo ago
Ovarian Ca
Interim
2027-11-13 · 1.6y away
Ovarian Ca
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07254783 | Phase 1 | Ovarian Ca | Active | 2270 | NT-proBNP |
| NCT03317682 | Phase 1 | Ovarian Ca | Not yet recr... | 1090 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn |